These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 497524)

  • 21. Prolongation of barbiturate-induced sleeping time in mice by dimethylformamide (DMF) and other non-polar solvents: absence of an effect on hepatic barbiturate-metabolising enzymes.
    Weetman DF; Crossfield C
    Methods Find Exp Clin Pharmacol; 1982; 4(2):99-103. PubMed ID: 7121125
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of propranolol, pindolol and atenolol after multiple administration in rats on the duration of hexobarbital sleeping time and on the activity of some drug-metabolizing enzyme systems.
    Kastelova A; Stoytchev T
    Acta Physiol Pharmacol Bulg; 1993; 19(4):101-4. PubMed ID: 8203279
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interactions of tricyclic antidepressants and barbiturates in barbiturate-tolerant and nontolerant rats.
    Liu SJ; Huang CL; Waters IW
    J Pharmacol Exp Ther; 1975 Aug; 194(2):285-95. PubMed ID: 1151759
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of Corynebacterium parvum vaccine on drug metabolism in the mouse.
    Macnee CM; Nimmo-Smith RH
    Dev Biol Stand; 1977 Apr 13-15; 38():427-30. PubMed ID: 608533
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of cannabidiol on cytochrome P-450 and hexobarbital sleep time.
    Bornheim LM; Borys HK; Karler R
    Biochem Pharmacol; 1981 Mar; 30(5):503-7. PubMed ID: 7225146
    [No Abstract]   [Full Text] [Related]  

  • 26. 5-Lipoxygenase and anandamide hydrolase (FAAH) mediate the antitumor activity of cannabidiol, a non-psychoactive cannabinoid.
    Massi P; Valenti M; Vaccani A; Gasperi V; Perletti G; Marras E; Fezza F; Maccarrone M; Parolaro D
    J Neurochem; 2008 Feb; 104(4):1091-100. PubMed ID: 18028339
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Interaction of the complex copper compound Cu-2 with liver monooxygenases].
    Bogush TA; Donenko FV; Sitdikova SM; Andronova NV
    Biull Eksp Biol Med; 1987 Oct; 104(10):438-40. PubMed ID: 3676462
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition and induction of hepatic drug metabolism in rats and mice by nafimidone and its major metabolite nafimidone alcohol.
    Rush WR; Smith SA; Mulvey JH; Graham DJ; Chaplin MD
    Drug Metab Dispos; 1987; 15(4):571-8. PubMed ID: 2888633
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of dietary lipid on drug-metabolizing enzymes.
    Wade AE; Norred WP
    Fed Proc; 1976 Nov; 35(13):2475-9. PubMed ID: 824158
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recovery from dispositional and pharmacodynamic tolerance after chronic pentobarbital treatment.
    Okamoto M; Rao SN; Reyes J; Rifkind AB
    J Pharmacol Exp Ther; 1985 Oct; 235(1):26-31. PubMed ID: 4045724
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of endotoxin-tolerance on in vivo drug metabolism in mice.
    Abernathy CO; Zimmerman HJ; Utili R
    Res Commun Chem Pathol Pharmacol; 1980 Jul; 29(1):193-6. PubMed ID: 7403675
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of experimental diabetes on drug metabolism in the rat.
    Ackerman DM; Leibman KC
    Drug Metab Dispos; 1977; 5(4):405-10. PubMed ID: 19220
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metabolic and psychophysiologic studies of cannabidiol-hexobarbital interaction.
    Benowitz NL; Nguyen TL; Jones RT; Herning RI; Bachman J
    Clin Pharmacol Ther; 1980 Jul; 28(1):115-20. PubMed ID: 7389248
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of two cannabinoids on hepatic microsomal cytochrome P-450.
    Watanabe K; Hamajima K; Narimatsu S; Yamamoto I; Yoshimura H
    J Pharmacobiodyn; 1986 Jan; 9(1):39-45. PubMed ID: 3012058
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Use of synthetic steroids, inhibitors of microsomal enzymes, for retention of hexenal in the body and for prolongation of hexenal anesthesia under experimental conditions].
    Manankova NM; Nedel'kina SV; Kozhemiakina NN; Salganik RI
    Vopr Med Khim; 1976; 22(6):740-6. PubMed ID: 68623
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A survey of the response of different strains of mice to substances metabolised by microsomal oxidation; hexobarbitone, zoxazolamine and warfarin.
    Lush IE
    Chem Biol Interact; 1976 Mar; 12(3-4):363-73. PubMed ID: 1253337
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Self-catalyzed inactivation of cytochrome P-450 during microsomal metabolism of cannabidiol.
    Watanabe K; Arai M; Narimatsu S; Yamamoto I; Yoshimura H
    Biochem Pharmacol; 1987 Oct; 36(20):3371-7. PubMed ID: 3675599
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibitory effect of cannabidiol hydroxy-quinone, an oxidative product of cannabidiol, on the hepatic microsomal drug-metabolizing enzymes of mice.
    Watanabe K; Usami N; Yamamoto I; Yoshimura H
    J Pharmacobiodyn; 1991 Jul; 14(7):421-7. PubMed ID: 1802990
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sexual dimorphism and the effects of the X-linked Tfm locus on hexobarbitone metabolism and action in mice.
    King DK; Shapiro BH
    Br J Pharmacol; 1981 Sep; 74(1):97-104. PubMed ID: 7196788
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Sex difference in the effects of delta 9-tetrahydrocannabinol and cannabidiol on pentobarbital-induced sleeping time and hepatic microsomal drug metabolizing enzyme systems in mice].
    Hamajima K; Watanabe K; Narimatsu S; Tateoka Y; Yamamoto I; Yoshimura H
    Yakugaku Zasshi; 1983 Dec; 103(12):1289-97. PubMed ID: 6330340
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.